- Home
- CADL vs SLN Comparison
CADL vs SLN Comparison
Compare CADL & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- SLN
- Stock Information
- Founded
- CADL 1999
- SLN 1994
- Country
- CADL United States
- SLN United Kingdom
- Employees
- CADL N/A
- SLN N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- SLN Health Care
- Exchange
- CADL Nasdaq
- SLN Nasdaq
- Market Cap
- CADL 339.8M
- SLN 345.3M
- IPO Year
- CADL 2021
- SLN N/A
- Fundamental
- Price
- CADL $5.64
- SLN $7.24
- Analyst Decision
- CADL Strong Buy
- SLN Buy
- Analyst Count
- CADL 7
- SLN 6
- Target Price
- CADL $19.57
- SLN $39.67
- AVG Volume (30 Days)
- CADL 841.7K
- SLN 185.8K
- Earning Date
- CADL 11-14-2025
- SLN 11-07-2025
- Dividend Yield
- CADL N/A
- SLN N/A
- EPS Growth
- CADL N/A
- SLN N/A
- EPS
- CADL N/A
- SLN N/A
- Revenue
- CADL N/A
- SLN $27,169,000.00
- Revenue This Year
- CADL N/A
- SLN N/A
- Revenue Next Year
- CADL N/A
- SLN N/A
- P/E Ratio
- CADL N/A
- SLN N/A
- Revenue Growth
- CADL N/A
- SLN 22.28
- 52 Week Low
- CADL $3.79
- SLN $1.97
- 52 Week High
- CADL $14.60
- SLN $18.29
- Technical
- Relative Strength Index (RSI)
- CADL 51.71
- SLN 68.03
- Support Level
- CADL $5.35
- SLN $7.06
- Resistance Level
- CADL $5.80
- SLN $7.75
- Average True Range (ATR)
- CADL 0.37
- SLN 0.52
- MACD
- CADL -0.01
- SLN 0.06
- Stochastic Oscillator
- CADL 42.40
- SLN 82.66
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.